Research programme: cannabinoid receptor CB2 agonists - Amgen
Latest Information Update: 06 Apr 2011
At a glance
- Originator Amgen
- Class Oxadiazoles; Piperidines
- Mechanism of Action Cannabinoid receptor CB2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Sep 2008 Preclinical trials in Pain in USA (PO)